The Glucagon‐Like Peptides

Brubaker, Patricia L.

doi:10.1196/annals.1317.006

Cited by 89 publications

(57 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GLP‐1 is secreted from intestinal L cells in response to ingestion of nutrients, including carbohydrate and lipids 5 . A previous study showed that alpha‐linolelic acid (α‐LA) promoted GLP‐1 secretion through the stimulation of G‐protein‐coupled receptor (GPR) 120, which is abundantly expressed in the intestine, in mice 6 .…”

Section: Introductionmentioning

confidence: 99%

Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations

Senmaru

Fukui

Kobayashi

et al. 2012

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/Introduction: Eicosapentaenoic acid (EPA) stimulates glucagon‐like peptide‐1 (GLP‐1) secretion in mice. We investigated the relationship between serum EPA concentrations and the efficacy of dipeptidyl‐peptidase IV (DPP‐4) inhibitor in patients with type 2 diabetes.Materials and Methods: Serum EPA concentrations were measured in 62 consecutive patients with type 2 diabetes who were newly given DPP‐4 inhibitor as a monotherapy or as an add‐on therapy to oral hypoglycemic agents. The dosage of oral hypoglycemic agents was maintained during the observation period. After 24 weeks of treatment with DPP‐4 inhibitor, we evaluated the relationships between a decrease in hemoglobin A1c from baseline and serum EPA concentrations, as well as age, sex, body mass index (BMI), hemoglobin A1c at baseline and usage of antidiabetic concomitant drugs.Results: Hemoglobin A1c was significantly decreased from 8.1 ± 1.1% to 7.2 ± 1.0% by DPP‐4 inhibitor. A decrease in hemoglobin A1c correlated with BMI (r = −0.396, P = 0.0013), age (r = 0.275, P = 0.0032), hemoglobin A1c at baseline (r = 0.490, P < 0.0001) and log EPA (r = 0.285, P = 0.0246). Multiple regression analysis showed that BMI (β = −0.419, P = 0.0002), hemoglobin A1c at baseline (β = 0.579, P < 0.0001) and log EPA (β = 0.220, P = 0.0228) were independent determinants of decrease in hemoglobin A1c.Conclusions: DPP‐4 inhibitor is effective in patients with type 2 diabetes with high serum EPA concentrations. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2012.00220.x , 2012)

show abstract

Section: Introductionmentioning

confidence: 99%

Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations

Senmaru

Fukui

Kobayashi

et al. 2012

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…In the CNS the GLP2R is expressed in the hypothalamic nucleus, the hippocampus, the nucleus of the solitary tract, the parabrachial nucleus, the supramammillary nucleus, and the substantia nigra (Vrang & Larsen 2010). The main stimulus for the GLP2 release is represented by the presence of nutrients, specifically fats and carbohydrates, in the intestinal lumen (Brubaker 2006). After secretion, GLP2 is degraded by the enzyme dipeptidyl peptidase-IV (DPP-IV), which renders the peptide inactive by N-terminal truncation of the alanine at position 2 .…”

Section: Introductionmentioning

confidence: 99%

Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2

Baldassano¹,

Bellanca²,

Serio³

et al. 2012

Journal of Endocrinology

View full text Add to dashboard Cite

We investigated the potential anorectic action of peripherally administered glucagon-like peptide 2 (GLP2) in lean and diet-induced obese (DIO) mice. Mice, fasted for 16 h, were injected i.p. with native GLP2 or [Gly 2 ]GLP2, stable analog of GLP2, before or after GLP2 (3-33), a GLP2 receptor (GLP2R) antagonist, or exendin (9-39), a GLP1R antagonist. Food intake was measured at intervals 1, 2, 4, 8, and 24 h postinjection. In addition, we tested in lean mice the influence of [Gly 2 ]GLP2 on gastric emptying and the effects of GLP1 alone or in combination with [Gly 2 ]GLP2 on food intake. [Gly 2 ]GLP2 dose dependently and significantly inhibited food intake in lean and DIO mice. The reduction of food intake occurred in the first hour postinjection and it was sustained until 4 h postinjection in lean mice while it was sustained until 2 h postinjection in DIO mice. GLP2 significantly inhibited food intake in both lean and DIO mice but only in the first hour postinjection. ]GLP2 decreased the gastric emptying rate. Results suggest that GLP2 can reduce food intake in mice in the short term, likely acting at a peripheral level. DIO mice are less sensitive to the anorectic effect of the peptide.

show abstract

“…[4][5][6] The primary stimulus of incretin secretion is food consumption, in particular fat and carbohydrate. 7 The action of incretins is insulin dependent and ends when glucose levels are <55 mg/dL. 8 The effect of DPP4 inhibitors may be mediated via enhancement of GLP-1 secretion.…”

Section: Incretin Hormonesmentioning

confidence: 99%

DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy

Argyrakopoulou¹,

Doupis

2009

Adv Therapy

View full text Add to dashboard Cite

Diabetes mellitus (DM) is currently considered to be an epidemic disease. A safe and effective treatment has long been sought by scientists. Incretin mimetics and dipeptidyl peptidase-4 (DPP4) inhibitors represent a new class of agents that have recently been included as antidiabetic drugs. Although only a limited number of studies exist regarding the treatment of DM based on the incretin effect, DPP4 inhibitors have so far proved to be safe and effective, both when administered alone or in combination with other antidiabetic medication. This review focuses on incretin-effect physiology, as well as the DPP4 inhibitors, from sitagliptin to the new alogliptin-pioglitazone combination agent, given as monotherapy and in combination with other antidiabetic agents.

show abstract

The Glucagon‐Like Peptides

Cited by 89 publications

References 126 publications

Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations

Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations

Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2

DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy

Contact Info

Product

Resources

About